drugset

drugset / Trial / NCT00831779

Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

NCT00831779 ↗

Phase 2 Completed 116 enrolled AstraZeneca Astra Zeneca, Bristol-Myers Squibb · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effects of dapagliflozin on insulin sensitivity

Timeline

Start: 2009-04
Primary completion: 2010-08
Completion: 2010-08

Outcome

Met primary endpoint

registry Placebo + Background Anti-Diabetes Medication vs Dapagliflozin 5 mg + Background Anti-Diabetes Medication; p = 0.0059 NCT00831779 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dapagliflozin	Small molecule	5 mg	Oral

Indications